Publications by authors named "Meshary Almeshary"
The Impact of Sacubitril/Valsartan on Heart Failure Patient with Reduced Left Ventricular Ejection Fraction: Single Center Retrospective Study in Saudi Arabia.
Drug Healthc Patient Saf
September 2024
Article Synopsis
- Sacubitril/valsartan (S/V) is a medication for heart failure with reduced ejection fraction (HFrEF), aimed at improving heart function and reducing hospitalizations.* -
- A study with 107 patients showed no significant improvement in left ventricular ejection fraction (LVEF) after using S/V, although hospitalizations due to heart failure symptoms decreased numerically.* -
- Overall, S/V was well tolerated but did not demonstrate a strong benefit for LVEF improvement, suggesting that heart failure clinics should carefully manage dosing for optimal results.*
Background: Thrombosis is the abnormal formation of blood clots within blood vessels; it results from an imbalance between fibrinolytic, pro-coagulant, and anticoagulant systems. Pediatric arterial thrombosis, especially related to catheter usage, is an emerging issue with limited evidence. This study evaluates the efficacy of enoxaparin in treating arterial thrombosis in pediatric patients at a single center.
View Article and Find Full Text PDFBackground: Higher doses of vancomycin are currently prescribed due to the emergence of bacterial tolerance and resistance. This study aimed to evaluate the efficacy and safety of the currently adopted vancomycin dosing guide in pediatric cardiology.
Methods: This was a single-center prospective cohort study with pediatric cardiac patients, younger than 14 years, from June 2020 to March 2021.
The impact of child-specific characteristics on warfarin dosing requirements.
Res Pract Thromb Haemost
January 2024
Background: The influence of child characteristics on warfarin dosing has been reported; however, there is no consensus on the nature and extent of this effect.
Objectives: To investigate the impacts of the demographic and clinical characteristics of children on the warfarin dose required to achieve a therapeutic international normalization ratio (INR).
Methods: This retrospective cohort study included children aged 3 months to 14 years old who were prescribed warfarin for 3 months or longer with a "stable INR.